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T cells play a critical role in host defense against viruses,
intra- and extracellular microbes, and tumors. Because
foreign antigen is presented amongst a vast majority of
self-antigens, T cells have evolved the unique ability to
discriminate “self” from “non-self” with high sensitivity
and selectivity, enabling the elimination of foreign patho-
gens while largely avoiding self-reactivity. However, tis-
sue-specific autoimmunity and tolerance to or eradication
of cancer does not fit neatly into the self/non-self para-
digm because the T cell responses in these situations are
not directed to an exogenous pathogen, but rather most
often to non-mutated self-proteins.
Therefore, an important question is how the immune
system establishes suitable thresholds that allow positively
selected T cells to interact with self-ligands in the periph-
ery without causing overt activation. One hypothesis to
explain how a T cell distinguishes among different types
of self-ligands is the kinetic proof-reading theory, which
relates signaling efficacy to the life-time of the TCR (T cell
receptor)-pMHC (peptide-major histocompatibility
complex) interaction. More recently, T cell maturation
associated signaling feedback pathways have also been
hypothesized to play a role in T cell discrimination of
between self-ligands.
We are taking a variety of biophysical and cellular
imaging approaches to determine how specific thresholds
for T cell recognition of self-antigens are set. Our recent
results [1] indicate that antitumor activity and autoimmu-
nity are coupled and have a similar kinetic threshold; redu-
cing autoimmunity cannot be accomplished without
sacrificing efficacy of tumor killing. Therefore, an “optimal
TCR affinity range” that leads to optimal tumor regression
and minimal autoimmunity is elusive and treatment
strategies focusing on increasing TCR affinities to a supra-
physiological level has most likely little therapeutic benefit.
Therefore, other approaches are needed to improve the
balance between anti-tumor responses and autoimmunity.
Our strategy to overcome this issue includes novel
methods for careful biophysical engineering of tumor-
specific TCRs to carefully balance tumor-reactivity and
autoimmunity. Furthermore, our recent preliminary data
show that TCR-proximal signaling differs significantly
between effector memory and central memory T cells
due to differential constitutive activity and localization
of signaling molecules. Understanding how activation
signaling contributes to differences in memory T cell
subset sensitivity may provide insight into how T cells
can be manipulated to achieve optimal anti-tumor sensi-
tivity. This could lead to adjuvants that target and
enhance antigen-specific T cell anti-tumor efficacy.
Together may lead to development of cancer immu-
notherapy approaches with improved outcomes.
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